After building momentum for weeks, congressional action on patent reform legislation is beginning to slow. The Senate Judiciary Committee has twice postponed markup of the bi-partisan PATENT Act in recent weeks. Reportedly, one reason behind the pause is a push by the pharmaceutical industry to include amendments that would limit the Patent and Trademark Office’s (PTO) authority to reevaluate the validity of issued patents at the request of third-parties that haven’t themselves been accused of infringement.
top of page
Recent PostsSee All
In a comment letter sent to the USPTO, UFPR offers recommendations on how the agency’s work in the next four years can ensure that all Americans experience the benefits of innovation rather than feeli
UFPR Submits Comments to the USPTO on Initiatives for the Robustness and Reliability of Patent Right
United for Patent Reform submitted comments to the United States Patent and Trademark Office (USPTO) on the office’s initiatives to ensure the robustness and reliability of patent rights, offering str
United for Patent Reform submitted comments to the United States Patent and Trademark Office (USPTO) on the patent subject matter eligibility guidance. The letter addresses how the Examination Guidanc
bottom of page